New knee shot targets arthritis pain in early trial
NCT ID NCT07338266
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a single injection of AVD275, a new form of the pain reliever celecoxib, in 15 adults with knee osteoarthritis. The goal is to check safety and how the drug spreads in the body. Participants will be monitored for 24 weeks after the shot.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS OF THE KNEE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cognivus Research Group
RECRUITINGWahroonga, New South Wales, 2076, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ultrasound may predict which patients get poor pain relief from a common knee block
- Can a new Slow-Release ibuprofen tame knee arthritis pain for 12 hours?
- Steroid cocktail may offer better pain control after knee replacement
- Can a steroid cocktail beat the standard nerve block for knee replacement pain?
- Can a pinch of hydromorphone make knee surgery recovery less painful?
- Can the right anesthesia get knee replacement patients moving faster?